Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Operating Leases (2019 - 2025)

Zevra Therapeutics (ZVRA) has disclosed Operating Leases for 7 consecutive years, with $859000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Operating Leases rose 8.46% year-over-year to $859000.0, compared with a TTM value of $859000.0 through Dec 2025, up 8.46%, and an annual FY2025 reading of $859000.0, up 8.46% over the prior year.
  • Operating Leases was $859000.0 for Q4 2025 at Zevra Therapeutics, down from $1.6 million in the prior quarter.
  • Across five years, Operating Leases topped out at $1.6 million in Q4 2021 and bottomed at $456000.0 in Q4 2023.
  • Average Operating Leases over 5 years is $1.0 million, with a median of $851000.0 recorded in 2022.
  • The sharpest move saw Operating Leases crashed 46.91% in 2022, then surged 81.82% in 2024.
  • Year by year, Operating Leases stood at $1.6 million in 2021, then plummeted by 46.91% to $843000.0 in 2022, then crashed by 45.91% to $456000.0 in 2023, then skyrocketed by 73.68% to $792000.0 in 2024, then rose by 8.46% to $859000.0 in 2025.
  • Business Quant data shows Operating Leases for ZVRA at $859000.0 in Q4 2025, $1.6 million in Q2 2025, and $792000.0 in Q4 2024.